Compare GATX & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GATX | ICLR |
|---|---|---|
| Founded | 1898 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 8.2B |
| IPO Year | 1994 | 2001 |
| Metric | GATX | ICLR |
|---|---|---|
| Price | $198.34 | $102.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $215.50 | $178.62 |
| AVG Volume (30 Days) | 174.7K | ★ 992.7K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ 17.22 | N/A |
| EPS | ★ 9.12 | N/A |
| Revenue | ★ $1,740,400,000.00 | N/A |
| Revenue This Year | $42.21 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | $21.71 | ★ $12.91 |
| Revenue Growth | ★ 9.77 | N/A |
| 52 Week Low | $141.28 | $66.57 |
| 52 Week High | $205.56 | $211.00 |
| Indicator | GATX | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 69.19 | 39.35 |
| Support Level | $166.88 | $95.75 |
| Resistance Level | $199.00 | $114.75 |
| Average True Range (ATR) | 3.80 | 4.87 |
| MACD | 0.69 | -0.82 |
| Stochastic Oscillator | 70.27 | 13.20 |
GATX Corp leases transportation assets, including railcars, aircraft spare engines, and tank containers, to customers in North America, Europe, and India. The company's reportable business segments are: Rail North America, Rail International, Engine Leasing, and Other. The majority of its revenue is generated from the Rail North America segment, which is composed of the company's operations in the United States, Canada, and Mexico. This segment mainly provides railcars pursuant to full-service leases under which it maintains the railcars, pays ad valorem taxes and insurance, and provides other ancillary services.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.